🔎 Trials Near Me

Home › Acute Myeloid Leukemia › New York › Buffalo

Acute Myeloid Leukemia clinical trials in Buffalo, NY

19 studies for Acute Myeloid Leukemia are looking for participants at sites in and around Buffalo (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

RecruitingPhase 2
  • Roswell Park Cancer Institute, Buffalo
Ages 60 and older · All sexes · Updated Oct 2, 2026 · NCT07437950

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

RecruitingPhase 3
  • Roswell Park Comprehensive Cancer Center, Buffalo
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RecruitingPhase 2
  • Roswell Park Cancer Institute, Buffalo
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

RecruitingPhase 1
  • Roswell Park Cancer Institute, Buffalo
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06871410

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RecruitingPhase 2
  • Roswell Park Cancer Institute, Buffalo
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

RecruitingPhase 2
  • Roswell Park Cancer Institute, Buffalo
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RecruitingPhase 2
  • Roswell Park Cancer Institute, Buffalo
Ages 18 to 59 · All sexes · Updated Sep 22, 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RecruitingPhase 3
  • Roswell Park Cancer Institute, Buffalo
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

RecruitingPhase 1/2
  • Roswell Park Comprehensive Cancer Center, Buffalo
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06969430

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

RecruitingPhase 3
  • State University of New York at Buffalo, Buffalo
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

RecruitingPhase 1
  • Roswell Park Comprehensive Cancer Center, Buffalo
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

RecruitingPhase 2
  • Roswell Park Cancer Institute, Buffalo
Ages 18 and older · All sexes · Updated Jul 10, 2026 · NCT05442216

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

RecruitingObservational study
  • Roswell Park Cancer Institute, Buffalo
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

RecruitingPhase 2/3
  • Roswell Park Comprehensive Cancer Center, Buffalo
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

RecruitingPhase 1/2
  • Roswell Park Comprehensive Cancer Center, Buffalo
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RecruitingPhase 1
  • Roswell Park Comprehensive Cancer Center, Buffalo
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

RecruitingPhase 1
  • Roswell Park Cancer Institute, Buffalo
Ages 18 and older · All sexes · Updated Jan 16, 2026 · NCT05143996

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

RecruitingPhase 1
  • Roswell Park Cancer Institute, Buffalo
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT06501196

About Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.

More about Acute Myeloid Leukemia on MedlinePlus

Acute Myeloid Leukemia trials in other cities

Other studies in Buffalo

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.